Lantus Articles
Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"
23 November 2012
More news from American Diabetes Association meeting
13 June 2012
Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting
13 September 2011
Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations
10 February 2010
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings
30 October 2009
Wellstat could earn $350 million from Sanofi-Aventis deal for novel type 2 diabetes age
21 October 2009
Biosimilar insulins and analogs set to erode $6.1 billion in brand sales in the USA and Europe by 2018
15 October 2009
Sanofi-Aventis launches major insulin research program; updates on rimonabant court case
30 September 2009
Sanofi sees more China opportunities
24 April 2009
Sanofi invests $90M in Lantus plant in China
22 April 2009
Sanofi launches Apidra SoloSTAR in USA
21 April 2009
Record sales for Sanofi Japan, says president
14 April 2009
Sanofi's Apidra SoloSTAR cleared in the USA
9 March 2009
Lantus shows benefits over determir and NPH
15 September 2008
Sanofi-Aventis' second-quarter 2008 results disappoint analysts, hit by weak US dollar
11 August 2008
66% of Lantus patients meet ADA's 7% target
16 June 2008
Sanofi-Aventis
5 May 2008
UPDATE: Sanofi-Aventis to invest 100 million euros in new Chinese flu vaccine facility
3 December 2007
Liraglutide gives better control than Lantus
2 July 2007
FDA approves Sanofi's Lantus SoloStar
7 May 2007
Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results
6 November 2006
Global diabetes drug market worth $15B in 2005
22 May 2006
Sanofi-Aventis launches Apidra insulin in USA
13 March 2006
Sanofi-Aventis sales slow on competition
6 February 2006
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Positive results for Sanofi-Aventis' Lantus
20 June 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
Sanofi-Aventis scoops marketing awards
20 December 2004
FDA clears new delivery device for Aventis' Lantus
23 August 2004
Aventis to see if Lantus reduces CVD risk
1 March 2004
Aventis files insulin delivery device
23 February 2004
Aventis continues its transformation, comments broker
24 November 2003
Aventis' Lantus appro in Japan for diabetes
27 October 2003
Aventis puts timetable on sales of stakes in Clariant and Rhodia
29 September 2003
German drug industry investment stays high despite reform
29 September 2003
Aventis launches Lantus in India
22 September 2003
Novo Nordisk
8 September 2003
Majors rush to roll out new drugs in Japan
14 July 2003
Aventis' Lantus gets pediatric OK in EU
24 March 2003
UK NICE issues flu and diabetes guidances
3 March 2003
Aventis blockbusters driving growth
6 May 2002
Aventis unveils major new Lantus trials
22 April 2002
Stock Commentary - Europe
15 November 2001
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
Stock Commentary - Europe
7 June 2001
Aventis' Lantus launched in USA
24 May 2001
Aventis insulin plant
9 April 2001
Aventis resolves patent dispute with Novo Nordisk
1 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Stock Commentary Europe
22 June 2000
Aventis' basal insulin cleared in Europe
15 June 2000
Novo Nordisk taking Aventis to court
28 April 2000
Aventis gains US approval for Lantus
27 April 2000
Showing 1-89 of 89 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
